Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection
We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, wh...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2023-05, Vol.30 (3), p.177-179 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 179 |
|---|---|
| container_issue | 3 |
| container_start_page | 177 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 30 |
| creator | Fernández-Oliveira, Carla Rotea-Salvo, Sandra Fernández-Docampo, Marta González-Piñeiro, Sara Martín-Herranz, Isabel |
| description | We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused severe pneumonia and an explosive inflammatory reaction that required tocilizumab and remdesivir treatment, and a high-risk retroperitoneal haematoma. Recombinant porcine factor VIII, susoctocog alfa, was requested from the Pharmacy Service in view of the extreme risk of thromboembolism resulting from the concomitant inflammatory storm caused by SARS-CoV-2. Improvement in the SARS-CoV-2 infection made it possible to complete the immunosuppressive treatment with rituximab. The patient was discharged with mycophenolate mofetil as immunosuppressive treatment after 89 days in hospital and 22 days of treatment with susoctocog alfa. His SARS-CoV-2 infection resolved and the haematoma evolved favourably. |
| doi_str_mv | 10.1136/ejhpharm-2021-002805 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10176986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2529913711</sourcerecordid><originalsourceid>FETCH-LOGICAL-b518t-ec16bb2abca8938b6732af8ceb3a100ebaf2dc8d615f6711ffa887895f1b0b4c3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEolXpP0DIEhcuof5Iss4JVRUUpEpcytkaO-ONl8RO7WSr_Uf8TLzddvk4IE4eyc_7zozmLYrXjL5nTDQXuOmnHuJYcspZSSmXtH5WnHJarcq2barnx7puTorzlJymtRCyrUT7sjgRFWWsruvT4sdtRJhH9DMJlvRu3ZfRpe9ED4id82ty7-aepCUFMwcT1gQGC8R5AmSC2e11DwSYu8VF7EgPOIapd4MDcknAd5n0IcvD6GAgCbcYMePLjCRimlyEOcQdSTvfxTAiMSEGD1sXl0R47mTRzC74V8ULC0PC88f3rPj26ePt1efy5uv1l6vLm1LXTM4lGtZozUEbkK2QulkJDlYa1AIYpajB8s7IrmG1bVaMWQtSrmRbW6aprow4Kz4cfKdFj9iZvGGEQU3RjRB3KoBTf_5416t12CpG2appZZMd3j06xHC3YJrV6JLBYQCPYUmK17xtmcjNM_r2L3QTlujzfipfVEieTXmmqgNlYkgpoj1Ow6jax0E9xUHt46AOcciyN79vchQ9HT8DFwdAj5v_taS_FMdR_yn5CQej1tI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803821012</pqid></control><display><type>article</type><title>Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Fernández-Oliveira, Carla ; Rotea-Salvo, Sandra ; Fernández-Docampo, Marta ; González-Piñeiro, Sara ; Martín-Herranz, Isabel</creator><creatorcontrib>Fernández-Oliveira, Carla ; Rotea-Salvo, Sandra ; Fernández-Docampo, Marta ; González-Piñeiro, Sara ; Martín-Herranz, Isabel</creatorcontrib><description>We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused severe pneumonia and an explosive inflammatory reaction that required tocilizumab and remdesivir treatment, and a high-risk retroperitoneal haematoma. Recombinant porcine factor VIII, susoctocog alfa, was requested from the Pharmacy Service in view of the extreme risk of thromboembolism resulting from the concomitant inflammatory storm caused by SARS-CoV-2. Improvement in the SARS-CoV-2 infection made it possible to complete the immunosuppressive treatment with rituximab. The patient was discharged with mycophenolate mofetil as immunosuppressive treatment after 89 days in hospital and 22 days of treatment with susoctocog alfa. His SARS-CoV-2 infection resolved and the haematoma evolved favourably.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2021-002805</identifier><identifier>PMID: 34011555</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Animals ; Case Report ; clinical laboratory techniques ; Clinical trials ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; Cross Infection - diagnosis ; Cross Infection - drug therapy ; Drug dosages ; drug monitoring ; Drug stores ; drug-related side effects and adverse reactions ; Factor VIII - therapeutic use ; hematology ; Hematoma - drug therapy ; Hemophilia ; Hemophilia A - complications ; Hemophilia A - diagnosis ; Hemophilia A - drug therapy ; Hospitals ; Infections ; Male ; pharmaceutical preparations ; Pharmacists ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Swine ; Thromboembolism ; Thrombosis ; Vitamin E</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-05, Vol.30 (3), p.177-179</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage</rights><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b518t-ec16bb2abca8938b6732af8ceb3a100ebaf2dc8d615f6711ffa887895f1b0b4c3</citedby><cites>FETCH-LOGICAL-b518t-ec16bb2abca8938b6732af8ceb3a100ebaf2dc8d615f6711ffa887895f1b0b4c3</cites><orcidid>0000-0002-7860-4029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176986/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176986/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34011555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández-Oliveira, Carla</creatorcontrib><creatorcontrib>Rotea-Salvo, Sandra</creatorcontrib><creatorcontrib>Fernández-Docampo, Marta</creatorcontrib><creatorcontrib>González-Piñeiro, Sara</creatorcontrib><creatorcontrib>Martín-Herranz, Isabel</creatorcontrib><title>Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused severe pneumonia and an explosive inflammatory reaction that required tocilizumab and remdesivir treatment, and a high-risk retroperitoneal haematoma. Recombinant porcine factor VIII, susoctocog alfa, was requested from the Pharmacy Service in view of the extreme risk of thromboembolism resulting from the concomitant inflammatory storm caused by SARS-CoV-2. Improvement in the SARS-CoV-2 infection made it possible to complete the immunosuppressive treatment with rituximab. The patient was discharged with mycophenolate mofetil as immunosuppressive treatment after 89 days in hospital and 22 days of treatment with susoctocog alfa. His SARS-CoV-2 infection resolved and the haematoma evolved favourably.</description><subject>Animals</subject><subject>Case Report</subject><subject>clinical laboratory techniques</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>Cross Infection - diagnosis</subject><subject>Cross Infection - drug therapy</subject><subject>Drug dosages</subject><subject>drug monitoring</subject><subject>Drug stores</subject><subject>drug-related side effects and adverse reactions</subject><subject>Factor VIII - therapeutic use</subject><subject>hematology</subject><subject>Hematoma - drug therapy</subject><subject>Hemophilia</subject><subject>Hemophilia A - complications</subject><subject>Hemophilia A - diagnosis</subject><subject>Hemophilia A - drug therapy</subject><subject>Hospitals</subject><subject>Infections</subject><subject>Male</subject><subject>pharmaceutical preparations</subject><subject>Pharmacists</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Swine</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Vitamin E</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkk1v1DAQhiMEolXpP0DIEhcuof5Iss4JVRUUpEpcytkaO-ONl8RO7WSr_Uf8TLzddvk4IE4eyc_7zozmLYrXjL5nTDQXuOmnHuJYcspZSSmXtH5WnHJarcq2barnx7puTorzlJymtRCyrUT7sjgRFWWsruvT4sdtRJhH9DMJlvRu3ZfRpe9ED4id82ty7-aepCUFMwcT1gQGC8R5AmSC2e11DwSYu8VF7EgPOIapd4MDcknAd5n0IcvD6GAgCbcYMePLjCRimlyEOcQdSTvfxTAiMSEGD1sXl0R47mTRzC74V8ULC0PC88f3rPj26ePt1efy5uv1l6vLm1LXTM4lGtZozUEbkK2QulkJDlYa1AIYpajB8s7IrmG1bVaMWQtSrmRbW6aprow4Kz4cfKdFj9iZvGGEQU3RjRB3KoBTf_5416t12CpG2appZZMd3j06xHC3YJrV6JLBYQCPYUmK17xtmcjNM_r2L3QTlujzfipfVEieTXmmqgNlYkgpoj1Ow6jax0E9xUHt46AOcciyN79vchQ9HT8DFwdAj5v_taS_FMdR_yn5CQej1tI</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Fernández-Oliveira, Carla</creator><creator>Rotea-Salvo, Sandra</creator><creator>Fernández-Docampo, Marta</creator><creator>González-Piñeiro, Sara</creator><creator>Martín-Herranz, Isabel</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7860-4029</orcidid></search><sort><creationdate>20230501</creationdate><title>Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection</title><author>Fernández-Oliveira, Carla ; Rotea-Salvo, Sandra ; Fernández-Docampo, Marta ; González-Piñeiro, Sara ; Martín-Herranz, Isabel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b518t-ec16bb2abca8938b6732af8ceb3a100ebaf2dc8d615f6711ffa887895f1b0b4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Case Report</topic><topic>clinical laboratory techniques</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>Cross Infection - diagnosis</topic><topic>Cross Infection - drug therapy</topic><topic>Drug dosages</topic><topic>drug monitoring</topic><topic>Drug stores</topic><topic>drug-related side effects and adverse reactions</topic><topic>Factor VIII - therapeutic use</topic><topic>hematology</topic><topic>Hematoma - drug therapy</topic><topic>Hemophilia</topic><topic>Hemophilia A - complications</topic><topic>Hemophilia A - diagnosis</topic><topic>Hemophilia A - drug therapy</topic><topic>Hospitals</topic><topic>Infections</topic><topic>Male</topic><topic>pharmaceutical preparations</topic><topic>Pharmacists</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Swine</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Vitamin E</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández-Oliveira, Carla</creatorcontrib><creatorcontrib>Rotea-Salvo, Sandra</creatorcontrib><creatorcontrib>Fernández-Docampo, Marta</creatorcontrib><creatorcontrib>González-Piñeiro, Sara</creatorcontrib><creatorcontrib>Martín-Herranz, Isabel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández-Oliveira, Carla</au><au>Rotea-Salvo, Sandra</au><au>Fernández-Docampo, Marta</au><au>González-Piñeiro, Sara</au><au>Martín-Herranz, Isabel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>30</volume><issue>3</issue><spage>177</spage><epage>179</epage><pages>177-179</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused severe pneumonia and an explosive inflammatory reaction that required tocilizumab and remdesivir treatment, and a high-risk retroperitoneal haematoma. Recombinant porcine factor VIII, susoctocog alfa, was requested from the Pharmacy Service in view of the extreme risk of thromboembolism resulting from the concomitant inflammatory storm caused by SARS-CoV-2. Improvement in the SARS-CoV-2 infection made it possible to complete the immunosuppressive treatment with rituximab. The patient was discharged with mycophenolate mofetil as immunosuppressive treatment after 89 days in hospital and 22 days of treatment with susoctocog alfa. His SARS-CoV-2 infection resolved and the haematoma evolved favourably.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>34011555</pmid><doi>10.1136/ejhpharm-2021-002805</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-7860-4029</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2023-05, Vol.30 (3), p.177-179 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10176986 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Animals Case Report clinical laboratory techniques Clinical trials Coronaviruses COVID-19 COVID-19 - complications Cross Infection - diagnosis Cross Infection - drug therapy Drug dosages drug monitoring Drug stores drug-related side effects and adverse reactions Factor VIII - therapeutic use hematology Hematoma - drug therapy Hemophilia Hemophilia A - complications Hemophilia A - diagnosis Hemophilia A - drug therapy Hospitals Infections Male pharmaceutical preparations Pharmacists SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Swine Thromboembolism Thrombosis Vitamin E |
| title | Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20high-risk%20bleeding%20with%20susoctocog%20alfa%20in%20a%20patient%20with%20acquired%20haemophilia%20A%20and%20a%20nosocomial%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Fern%C3%A1ndez-Oliveira,%20Carla&rft.date=2023-05-01&rft.volume=30&rft.issue=3&rft.spage=177&rft.epage=179&rft.pages=177-179&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2021-002805&rft_dat=%3Cproquest_pubme%3E2529913711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2803821012&rft_id=info:pmid/34011555&rfr_iscdi=true |